Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin

Joop E Arends; Justin H Fransen; Andy I M Hoepelman; Debbie van Baarle

doi:10.1016/j.ijantimicag.2011.08.010

Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin

Joop E Arends^*, Justin H Fransen, Andy I M Hoepelman, Debbie van Baarle

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

Host polymorphisms in the IL28B region have recently been associated with outcome of treatment for hepatitis C virus (HCV) infection. This study clearly shows an association between first-phase viral load decrease and the IL28B rs12979860 polymorphism in chronic HCV-infected patients. Furthermore, a higher treatment efficiency factor (ɛ) was found in those HCV-infected patients with a CC genotype compared with those with a CT and TT genotype. This study highlights the importance of host response mechanisms in relation to favourable clearance of HCV.

Original language	English
Pages (from-to)	538-539
Number of pages	2
Journal	International journal of antimicrobial agents
Volume	38
Issue number	6
DOIs	https://doi.org/10.1016/j.ijantimicag.2011.08.010
Publication status	Published - Dec-2011
Externally published	Yes

Keywords

Antiviral Agents/therapeutic use
Hepacivirus/drug effects
Hepatitis C, Chronic/drug therapy
Humans
Interferon alpha-2
Interferon-alpha/therapeutic use
Interferons
Interleukins/genetics
Polyethylene Glycols/therapeutic use
Polymorphism, Single Nucleotide/genetics
Recombinant Proteins/therapeutic use
Ribavirin/therapeutic use
Treatment Outcome
Viral Load/drug effects

Access to Document

10.1016/j.ijantimicag.2011.08.010

Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b ribavirinFinal publisher's version, 217 KBLicence: Taverne

Cite this

@article{01080dfb7b914455ad7df7abfe4e3116,

title = "Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin",

abstract = "Host polymorphisms in the IL28B region have recently been associated with outcome of treatment for hepatitis C virus (HCV) infection. This study clearly shows an association between first-phase viral load decrease and the IL28B rs12979860 polymorphism in chronic HCV-infected patients. Furthermore, a higher treatment efficiency factor (ɛ) was found in those HCV-infected patients with a CC genotype compared with those with a CT and TT genotype. This study highlights the importance of host response mechanisms in relation to favourable clearance of HCV.",

keywords = "Antiviral Agents/therapeutic use, Hepacivirus/drug effects, Hepatitis C, Chronic/drug therapy, Humans, Interferon alpha-2, Interferon-alpha/therapeutic use, Interferons, Interleukins/genetics, Polyethylene Glycols/therapeutic use, Polymorphism, Single Nucleotide/genetics, Recombinant Proteins/therapeutic use, Ribavirin/therapeutic use, Treatment Outcome, Viral Load/drug effects",

author = "Arends, {Joop E} and Fransen, {Justin H} and Hoepelman, {Andy I M} and {van Baarle}, Debbie",

year = "2011",

month = dec,

doi = "10.1016/j.ijantimicag.2011.08.010",

language = "English",

volume = "38",

pages = "538--539",

journal = "International Journal of Microbial Agents",

issn = "0924-8579",

publisher = "Elsevier Bedrijfsinformatie b.v.",

number = "6",

}

Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin. / Arends, Joop E; Fransen, Justin H; Hoepelman, Andy I M; van Baarle, Debbie.

In: International journal of antimicrobial agents, Vol. 38, No. 6, 12.2011, p. 538-539.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin

AU - Arends, Joop E

AU - Fransen, Justin H

AU - Hoepelman, Andy I M

AU - van Baarle, Debbie

PY - 2011/12

Y1 - 2011/12

N2 - Host polymorphisms in the IL28B region have recently been associated with outcome of treatment for hepatitis C virus (HCV) infection. This study clearly shows an association between first-phase viral load decrease and the IL28B rs12979860 polymorphism in chronic HCV-infected patients. Furthermore, a higher treatment efficiency factor (ɛ) was found in those HCV-infected patients with a CC genotype compared with those with a CT and TT genotype. This study highlights the importance of host response mechanisms in relation to favourable clearance of HCV.

AB - Host polymorphisms in the IL28B region have recently been associated with outcome of treatment for hepatitis C virus (HCV) infection. This study clearly shows an association between first-phase viral load decrease and the IL28B rs12979860 polymorphism in chronic HCV-infected patients. Furthermore, a higher treatment efficiency factor (ɛ) was found in those HCV-infected patients with a CC genotype compared with those with a CT and TT genotype. This study highlights the importance of host response mechanisms in relation to favourable clearance of HCV.

KW - Antiviral Agents/therapeutic use

KW - Hepacivirus/drug effects

KW - Hepatitis C, Chronic/drug therapy

KW - Humans

KW - Interferon alpha-2

KW - Interferon-alpha/therapeutic use

KW - Interferons

KW - Interleukins/genetics

KW - Polyethylene Glycols/therapeutic use

KW - Polymorphism, Single Nucleotide/genetics

KW - Recombinant Proteins/therapeutic use

KW - Ribavirin/therapeutic use

KW - Treatment Outcome

KW - Viral Load/drug effects

U2 - 10.1016/j.ijantimicag.2011.08.010

DO - 10.1016/j.ijantimicag.2011.08.010

M3 - Article

C2 - 21974859

VL - 38

SP - 538

EP - 539

JO - International Journal of Microbial Agents

JF - International Journal of Microbial Agents

SN - 0924-8579

IS - 6

ER -